[show abstract][hide abstract] ABSTRACT: Sonoelastography (SEG) is a noninvasive ultrasound (US) method able to differentiate tissues according to their stiffness. Our objective was to establish whether transrectal (TR) SEG may improve prostate cancer detection, alone or associated with other US methods.
We analyzed the data of 65 patients, mean age 68 years (49 - 81 years), examined March 2009-September 2010. The patients had at least one of the following malignancy suspicion criteria: PSA > 4 ng /ml (minimum 2 determinations), nodule(s) at digital rectal examination (DRE +) or previous gray scale TRUS positive appearance. All patients underwent TRUS, Doppler-US and SEG in the same session, followed by systematic prostate biopsies (6-12 cores). Histopathology and imaging findings were correlated.
Twenty-eight out of 65 patients (43%) were diagnosed with prostate cancer. Overall, SEG had a sensitivity of 67.85%, specificity 62.16%, positive predictive value 57.57% and negative predictive value 71.85%. However, SEG diagnostic reliability appeared to be higher for subgroups of patients having PSA >10 ng / ml, lower number of fragments collected by PBP (6 vs. 10-12 cores) and age > 70 years.
SEG appears to be useful in the diagnosis of prostate cancer as it may increase the diagnosis accuracy in specific target groups.
[show abstract][hide abstract] ABSTRACT: Prostate cancer represents the first leading cause of cancer among western male population, with different clinical behavior ranging from indolent to metastatic disease. Although many molecules and deregulated pathways are known, the molecular mechanisms involved in the development of prostate cancer are not fully understood. The aim of this study was to explore the molecular variation underlying the prostate cancer, based on microarray analysis and bioinformatics approaches. Normal and prostate cancer tissues were collected by macrodissection from prostatectomy pieces. All prostate cancer specimens used in our study were Gleason score 7. Gene expression microarray (Agilent Technologies) was used for Whole Human Genome evaluation. The bioinformatics and functional analysis were based on Limma and Ingenuity software. The microarray analysis identified 1119 differentially expressed genes between prostate cancer and normal prostate, which were up- or down-regulated at least 2-fold. P-values were adjusted for multiple testing using Benjamini-Hochberg method with a false discovery rate of 0.01. These genes were analyzed with Ingenuity Pathway Analysis software and were established 23 genetic networks. Our microarray results provide new information regarding the molecular networks in prostate cancer stratified as Gleason 7. These data highlighted gene expression profiles for better understanding of prostate cancer progression.
Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie 01/2011; 52(4):1195-202. · 0.62 Impact Factor
[show abstract][hide abstract] ABSTRACT: Studies that analyze the levels of osteoprotegerin (OPG) or receptor activator of nuclear factor kappa B ligand (RANKL) in hypogonadal men, the majority of whom have prostate cancer or are undergoing androgen-deprivation therapy, are few and inconclusive.
81 men aged 69.3 ± 0.8 years (39 men with late-onset hypogonadism and 42 age-matched controls) were recruited. Serum levels of OPG, total soluble RANKL (sRANKL), total and free testosterone (FT), estradiol (E2), sex hormone-binding globulin (SHBG), follicle-stimulating hormone, luteinizing hormone (LH), prolactin, bone-specific alkaline phosphatase (BAP) and β-Cross Laps were assessed.
Compared with controls, both OPG (p = 0.023) and sRANKL (p = 0.010) serum levels were increased in men with late-onset hypogonadism; however, when expressed as a ratio, sRANKL/OPG, the two groups were not significantly different. Simple and age-adjusted analyses showed that OPG was inversely related to FT and positively related to SHBG, E2 and BAP. In the patient population, LH demonstrated statistically significant correlations with both OPG (r = 0.274, p = 0.013) and sRANKL (r = 0.276, p = 0.018). Multiple regression analysis retained age, SHBG, E2 and BAP as independent predictors of OPG, explaining 27.71% of serum OPG variability.
Late-onset hypogonadism is associated with enhanced RANKL activity. Increased bone turnover-related OPG levels may act as a coupling factor between bone resorption and formation. The results suggest anti-RANKL-agents as therapeutic tools in osteoporotic men with late-onset hypogonadism.
Clinical and investigative medicine. Medecine clinique et experimentale 01/2011; 34(4):E232. · 1.15 Impact Factor
[show abstract][hide abstract] ABSTRACT: Objective: The goal of this study was to determine if the concentrations of a set of 8 angiogenic molecules (plateletderived growth factor-BB (PDGF-BB), vascular endothelial growth factor, basic fibroblast growth factor, angiogenin, keratinocyte growth factor (KGF), tissue inhibitor of metalloproteinases-1 (TIMP-1), intercellular adhesion molecule-1, angiopoietin-2) in serum can be used as a noninvasive diagnostic test for prostate pathology in addition to use of the prostate specific antigen value, abnormal digital rectal examination, and pathological confirmation. Materials and Methods: Sera from 40 patients without cancer (control group), with prostate cancer, with benign prostatic hyperplasia, or with chronic prostatitis were used for FAST Quant® (Whatman) analysis. Results: The Shapiro-Wilk test was used for testing the normality of distribution. Angiopoietin-2, KGF, PDFG-BB, and TIMP-1 showed normal distributions (p > 0.05). Our results showed that there are significant serum concentration differences between prostate cancer, benign prostatic hyperplasia, chronic prostatitis, and the control group for the angiogenic molecules KGF, angiopoietin-2, PDFG-BB, and TIMP-1. Conclusion: Our data suggest that FAST Quant® (Whatman) analysis of multiple serum biomarkers consisting of angiogenesis molecules can improve the diagnosis of prostate pathology in a noninvasive manner.